Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.

Tarhini AA, Kirkwood JM.

Oncology (Williston Park). 2010 Dec;24(14):1302, 1304. No abstract available.

2.

Ipilimumab for advanced melanoma: let's not throw caution to the winds.

Lowe M, Delman KA.

Oncology (Williston Park). 2010 Dec;24(14):1296, 1299. No abstract available.

3.

Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.

[No authors listed]

Nat Rev Drug Discov. 2010 Aug;9(8):584. doi: 10.1038/nrd3245. No abstract available.

PMID:
20671754
4.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J.

Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Review.

5.

Ipilimumab: a promising immunotherapy for melanoma.

Thumar JR, Kluger HM.

Oncology (Williston Park). 2010 Dec;24(14):1280-8. Review.

6.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.

PMID:
21074069
7.

Improving the therapeutic benefits of ipilimumab.

Subudhi SK, Callahan MK, Wolchok JD.

Oncology (Williston Park). 2010 Dec;24(14):1288, 1294. No abstract available.

8.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, CalabrĂ² L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
9.

CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.

Phan GQ, Weber JS, Sondak VK.

Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Epub 2008 Aug 21. Review.

PMID:
18716842
10.

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

Lens M, Ferrucci PF, Testori A.

Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):105-13. Review.

PMID:
18537753
11.
13.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

14.

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J.

Oncologist. 2007 Jul;12(7):873-83. Review.

15.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).

Ribas A.

Oncologist. 2008;13 Suppl 4:10-5. doi: 10.1634/theoncologist.13-S4-10. Review.

16.

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.

Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D.

Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003. Review. Erratum in: Semin Oncol. 2012 Oct;39(5):625.

PMID:
21074064
17.

Ipilimumab.

Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P.

Nat Rev Drug Discov. 2011 Jun;10(6):411-2. doi: 10.1038/nrd3463. No abstract available.

PMID:
21629286
18.

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Robert C, Ghiringhelli F.

Oncologist. 2009 Aug;14(8):848-61. doi: 10.1634/theoncologist.2009-0028. Epub 2009 Aug 1. Review.

19.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.

20.

Ipilimumab for advanced melanoma: a nursing perspective.

Ledezma B.

Oncol Nurs Forum. 2009 Jan;36(1):97-104. doi: 10.1188/09.ONF.97-104. Review.

PMID:
19136343

Supplemental Content

Support Center